FDA Approves Cymbalta(R) For The Management Of Fibromyalgia (Medical News Today)
The U.S. Food and Drug Administration (FDA) has approved Cymbalta(R) (duloxetine HCl) for the management of fibromyalgia, a chronic widespread pain disorder, Eli Lilly and Company (NYSE: LLY) announced. Cymbalta is the first serotonin- norepinephrine reuptake inhibitor with proven efficacy for reducing pain in patients with fibromyalgia.

Two FDA drug approvals in two years catapult CV Therapeutics (BizJournals)
CV Therapeutics Inc. has enjoyed quite a turn of fortune almost a year after doubts about its angina drug Ranexa had the company considering "strategic alternatives."